TECHNOLOGY
The Latest Advancement in Neuromodulation
Transcranial focused ultrasound (tFUS) uses trusted technology to noninvasively target neural circuits precisely where it’s needed.
Transcranial Focused
Ultrasound
Benefits
Non-invasive treatment
Low risk with minimal discomfort
High-precision brain targeting
Personalized plans
More immediate relief
Minimal side effects
Medication-free
Trusted Technology
Sanmai's focused ultrasound device uses low-intensity waves similar to prenatal imaging, which is known for its safety. Instead of imaging, Sanmai’s device treats the brain using transcranial-focused ultrasound neuromodulation (tFUS). Researchers worldwide have published over forty studies on tFUS, addressing conditions like chronic pain, dementia, epilepsy, traumatic brain injury, depression, and anxiety.
The first depression clinical trial using the technology began in 2015 and was published by Saanmai co-founder Dr. Sanguinetti. Work continued with other mental health and brain disorders, including anxiety and dementia, continued by co-founder Dr. Kuhn.
60%
Of people with treatment-resistant GAD experienced clinically significant reduction in anxiety (Mahdavi et al., 2023)
70%
70% of patients with depression experienced increased mood after ultrasound in a pilot study
(Reznik, Sanguinetti, 2020)
Transcranial Focused
Ultrasound
Benefits
Non-invasive treatment
Low risk with minimal discomfort
High-precision brain targeting
Personalized plans
More immediate relief
Minimal side effects
Medication-free
Trusted Technology
Sanmai's focused ultrasound device uses low-intensity waves similar to prenatal imaging, which is known for its safety. Instead of imaging, Sanmai’s device treats the brain using transcranial-focused ultrasound neuromodulation (tFUS). Researchers worldwide have published over forty studies on tFUS, addressing conditions like chronic pain, dementia, epilepsy, traumatic brain injury, depression, and anxiety.
The first depression clinical trial using the technology began in 2015 and was published by Saanmai co-founder Dr. Sanguinetti. Work continued with other mental health and brain disorders, including anxiety and dementia, continued by co-founder Dr. Kuhn.
60%
Of people with treatment-resistant GAD experienced clinically significant reduction in anxiety (Mahdavi et al., 2023)
70%
70% of patients with depression experienced increased mood after ultrasound in a pilot study
(Reznik, Sanguinetti, 2020)
Promising Early Results
In our first pilot study using our prototype device, anxiety was significantly reduced in 73% of anxious participants during the first session.
This large effect lasted for 48 hours and was promising. We are now conducting a randomized, placebo-controlled trial with the Acacia Mental Health clinic to determine whether multiple sessions extend this effect in time.
Advancing the Clinical Technology
Research from our group and others shows that tFUS low-intensity waves can reach small targets deep inside the brain with significant neural and behavioral effects.
Our integrated acoustic planning software (pictured right) is designed to assist clinicians in individualizing the treatment for their patients with pinpoint targeting accuracy through GPU-accelerated ultrasound field simulations based on patient MRI.
Applicable tFUS Published Research
Meet Sanmai's team
World leaders in neuromodulation and ultrasound technology.